Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charisse Dolitsky

Dermatology Long Beach, NY Medical Doctor

NPI 1477510576 CMS profile 376614

604 E Park Ave, Long Beach, NY 11561

Open in the dashboard

General payments

$14,381

731 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charisse Dolitsky of Long Beach, NY is reported in the CMS Open Payments database as having received $14,381 across 731 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,943 134
2024 General $3,299 158
2023 General $2,913 159
2022 General $2,402 132
2021 General $1,278 77
2020 General $705 31
2019 General $842 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charisse Dolitsky
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Charisse Dolitsky were reported at $2,943. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Charisse Dolitsky Dermatology median Middle half National median
2019 $842 $454 $129–$1,240 $163
2020 $705 $235 $81–$756 $114
2021 $1,278 $377 $108–$1,108 $132
2022 $2,402 $514 $143–$1,391 $149
2023 $2,913 $607 $159–$1,674 $160
2024 $3,299 $751 $204–$1,903 $164
2025 $2,943 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,040 110 payments
  2. Novartis Pharmaceuticals Corporation $1,823 96 payments
  3. Lilly USA, LLC $1,143 67 payments
  4. Incyte Corporation $918 43 payments
  5. Janssen Biotech, Inc. $863 39 payments
  6. Biofrontera Inc. $829 46 payments
  7. E.R. Squibb & Sons, L.L.C. $754 38 payments
  8. Genzyme Corporation $741 30 payments
  9. Sun Pharmaceutical Industries Inc. $663 47 payments
  10. Amgen Inc. $644 24 payments
  11. Other $3,963 191 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,282 730 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. COSENTYX $1,027 53 payments
  2. SKYRIZI $1,023 59 payments
  3. DUPIXENT $1,011 41 payments
  4. TALTZ $1,005 60 payments
  5. OPZELURA $918 43 payments
  6. SOTYKTU $708 36 payments
  7. XEPI $698 39 payments
  8. TREMFYA $669 31 payments
  9. Otezla $644 24 payments
  10. VTAMA $643 41 payments
  11. Other $10,121 506 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,564

Median for Dermatology: 534

Drug cost

$104,119

Median for Dermatology: $67,151

Branded share of claims

6.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 18 $36,702
Crotan Crotamiton Brand 14 $16,596
Fluocinonide Generic 93 $6,512
Clobetasol Propionate Generic 98 $6,152
Ketoconazole Generic 187 $4,607
Ammonium Lactate Generic 136 $3,608
Fluorouracil Generic 50 $3,394
Clindamycin Phosphate Generic 55 $3,267
Triamcinolone Acetonide Generic 157 $3,075
Ciclopirox Ciclopirox Olamine Brand 44 $2,745

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$276,880

Of which drugs: $1,665

Medicare patients

868

Average age 74

Services billed

5,809

593 women, 275 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 47%
Ischemic heart disease 31%
Diabetes 28%
Osteoporosis 19%
Cancer 17%
Depression 17%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 60 90 $68

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
$359 — —
SOTYKTU
$354 — —
SKYRIZI
$297 — —
COSENTYX
$290 — —
Otezla
$276 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

731 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record